Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 5,818 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXTEND Clear all
Enrolling by invitation Phase 2 Interventional

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

NCT07286006
View directory record Official record
Conditions
Graves' Disease
Interventions
IMVT-1402
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
89
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional

Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome

NCT00593658
View directory record Official record
Conditions
Hepatopulmonary Syndrome
Interventions
pentoxifylline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

NCT04750226
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

NCT02662985
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 (secukinumab), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 18, 2026, 10:58 AM EDT
Terminated No phase listed Observational

EndoPredict® Extended Endocrine Trial (EXET)

NCT04016935
View directory record Official record
Conditions
Primary Invasive Breast Cancer
Interventions
Observational
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Burbank, California • Roseville, California • Fort Myers, Florida + 40 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

NCT02223052
View directory record Official record
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy

NCT04195438
View directory record Official record
Conditions
Liver Cancer
Interventions
CO Testing Pre/Post Hepatic Resection, ABG Testing Pre/Post Hepatic Resection, CT Evaluations
Procedure · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

NCT05635838
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 18, 2026, 10:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

NCT06249048
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
STX-001, Keytruda®
Biological
Lead sponsor
Strand Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

NCT02083185
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix, Leuprorelin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 18, 2026, 10:58 AM EDT
Terminated No phase listed Observational

Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections

NCT03080389
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
Interventions
Extended Urine Culture
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 18, 2026, 10:58 AM EDT
Enrolling by invitation Phase 3 Interventional

Long-Term Open-Label Extension Study of Oral Levosimendan

NCT07436689
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00334776
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 18, 2026, 10:58 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

QTc Study of Rosi XR in Healthy Volunteers

NCT00884533
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosi XR, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 18, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

NCT01834638
View directory record Official record
Conditions
Schizophrenia
Interventions
ABT-126
Drug
Lead sponsor
AbbVie
Industry
Eligibility
20 Years to 66 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Chino, California • Costa Mesa, California • Escondido, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

NCT01027949
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer

NCT01636284
View directory record Official record
Conditions
Hepatocellular Carinoma
Interventions
JX-594 recombinant vaccina GM-CSF
Biological
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 18, 2026, 10:58 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder

NCT03222752
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cranial Electrotherapy Stimulation, Sham Cranial Electrotherapy Stimulation
Device
Lead sponsor
Electromedical Products International, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Forest, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008

NCT00308438
View directory record Official record
Conditions
Crohn's Disease
Interventions
Teduglutide (ALX-0600)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
20
States / cities
Tucson, Arizona • Lakewood, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Rimegepant in Moderate Plaque-type Psoriasis

NCT04629950
View directory record Official record
Conditions
Psoriasis
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 18, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Open-label Extension to Protocol 1042-0500

NCT00442104
View directory record Official record
Conditions
Infantile Spasms
Interventions
Ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
4 Months to 24 Months
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Not applicable Interventional

SymptomCare@Home: Deconstructing an Effective Symptom Management Intervention

NCT02779725
View directory record Official record
Conditions
Cancer
Interventions
SCC, Nurse Practitioner, DSS, AT, Symptom Severity
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 18, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

BPL-003 Efficacy and Safety in Treatment Resistant Depression

NCT05870540
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
BPL-003
Drug
Lead sponsor
Beckley Psytech Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Rogers, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 10:58 AM EDT